Peptide Library

Human study PLS-00202

[The clinical significance of thymosin β4 expression in human non-small cell lung cancer].

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • [The clinical significance of thymosin β4 expression in human non-small cell lung cancer].primary · Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2004-12-01 · PMID 21251403 · DOI

Design and participants

Design
Other design
Population
Patients with non-small cell lung cancer whose paraffin-embedded tumour specimens and neighbouring noncancerous tissue were stained for endogenous Tβ4
Conditions
Non-small cell lung cancer
Setting
Pathology specimens (paraffin-embedded tissue); setting otherwise not stated
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no compound was administered

    The authors concluded (paraphrased): Lung cancer tissue overexpresses Tβ4. Expression relates to TNM stage, differentiation, metastasis and prognosis, so detecting it in tumour tissue may help predict prognosis.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Measures endogenous Tβ4 expression in tumour tissue rather than administration of Tβ4, so it gives no evidence on the effects of giving the compound.
    • abstract only: Only an English abstract of a Chinese-language article is available, and the prognosis result is truncated in the record.
    • small or imprecise: Only 76 specimens were analysed, with modest correlation coefficients for the clinicopathological associations.
    • inappropriate population: The study measured endogenous expression in tumour tissue and gave no Tβ4 to participants, so it cannot inform treatment effects or safety of administration.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 21251403, abstract (Conclusions) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 21251403, abstract (Methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 21251403, abstract (Methods and Results) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 21251403, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 21251403, abstract (Background and Methods) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).